Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin

被引：9

作者：

Bates, SM

Weitz, JI

机构：

[1] Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, Hamilton, ON L8V 1C3, Canada

[2] McMaster Univ, Hamilton, ON, Canada

来源：

CARDIOVASCULAR RESEARCH | 1999年 / 41卷 / 02期

基金：

英国医学研究理事会;

关键词：

coronary ischemic syndromes; thrombosis; anticoagulants; thrombin inhibitors; antiplatelet therapy; heparin; low-molecular-weight heparin; hirudin;

D O I：

10.1016/S0008-6363(98)00323-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：418 / 432

页数：15

共 127 条

[11]

BOISSEL JP, 1982, NEW ENGL J MED, V307, P701

[12]

Braunwald E, 1997, J AM COLL CARDIOL, V29, P1474

[13]

BREDDIN K, 1980, HAEMOSTASIS, V9, P325

[14] ANTITHROMBOTIC AGENTS IN CORONARY-ARTERY DISEASE [J].

CAIRNS, JA ;

LEWIS, HD ;

MEADE, TW ;

SUTTON, GC ;

THEROUX, P .

CHEST, 1995, 108 (04) :S380-S400

[15] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[16] A PILOT TRIAL OF RECOMBINANT DESULFATOHIRUDIN COMPARED WITH HEPARIN IN CONJUNCTION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI)-5 TRIAL [J].

CANNON, CP ;

MCCABE, CH ;

HENRY, TD ;

SCHWEIGER, MJ ;

GIBSON, RS ;

MUELLER, HS ;

BECKER, RC ;

KLEIMAN, NS ;

HAUGLAND, JM ;

ANDERSON, JL ;

SHARAF, BL ;

EDWARDS, SJ ;

ROGERS, WJ ;

WILLIAMS, DO ;

BRAUNWALD, E .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :993-1003

[17] REARRANGEABLE CIRCUIT-SWITCHED HYPERCUBE ARCHITECTURES FOR ROUTING PERMUTATIONS [J].

CHOI, SB ;

SOMANI, AK .

JOURNAL OF PARALLEL AND DISTRIBUTED COMPUTING, 1993, 19 (02) :125-130

[18] FLOW CYTOMETRIC OBSERVATIONS ON THE IN-VIVO USE OF FAB FRAGMENTS OF A CHIMERIC MONOCLONAL-ANTIBODY TO PLATELET GLYCOPROTEIN IIB-IIIA [J].

CHRISTOPOULOS, C ;

MACKIE, I ;

LAHIRI, A ;

MACHIN, S .

BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (05) :729-737

[19] A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].

Cohen, M ;

Demers, C ;

Gurfinkel, EP ;

Turpie, AGG ;

Fromell, GJ ;

Goodman, S ;

Langer, A ;

Califf, RM ;

Fox, KAA ;

Premmereur, J ;

Bigonzi, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452

[20]

Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730

← 1 2 3 4 5 6 7 8 9 10 →